ABBV Stock Analysis — AbbVie
Sector: Healthcare
AI Verdict
AbbVie trades at a steep discount to the sector median on forward earnings, so if its patent moat holds and the earnings snapback materializes, the current price is cheap for the growth you're getting.
Competitive Moat
AbbVie defends its profits with a portfolio of patent-protected drugs, most notably immunology blockbuster Humira, and a pipeline that leverages deep expertise in biologics and specialty pharmaceuticals. Its scale and established relationships with payers and providers create high barriers for new entrants.
Summary
A massive earnings rebound is expected, with forward EPS growth forecast at 666.1%.
Where It Stands
AbbVie has returned 17.70% over the past year, its RSI sits at 64.3 (near elevated territory), and it trades at 13.9x next year's earnings versus the healthcare sector median of 22x.
Key Metrics
- RSI: 64.3 — Near Overbought
- Trailing P/E: 106.5x
- Forward P/E: 13.9x
- PEG Ratio: 0.16
- Earnings Growth: +6.7%
- Revenue Growth: +0.1%
- Market Cap: $381.1B
- Dividend Yield: 0.03%
- 1-Year Return: 17.70%
- 52-Week High: $244.81
- 52-Week Low: $180.25
Analyst Consensus
30 Buy · 10 Hold · 0 Sell (40 analysts) · Target $276.25
Bull Case
The stock is cheap for the growth on offer, with a 13.9x forward P/E and consensus calling for 666.1% EPS growth next year as patent cliffs fade.
Bear Case
The trailing P/E of 106.5x means any disappointment in the expected earnings rebound could trigger a sharp P/E compression, especially with the RSI at 64.3 signaling pullback risk.
Catalyst to Watch
Watch for quarterly earnings and pipeline updates—any miss on the expected rebound or regulatory setbacks could break the growth narrative.